SBIR/STTR Research Award

Developing an Affordable and Pocketable POC Device for Monitoring Lithium and Sodium in Patients with Bipolar Disorder

Award identifier f9708820e9bdb2d68661bb7a11e72ddb09317cc96dcc1f6c3740395ca049b98cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$210,971

Program and phase

STTR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
GLUCOSENTIENT INC
Proposal award date
2016-08-01
Contract end date
2018-07-31
UEI
Z1GKW7XKS2P1
Solicitation number
PA15-270
Topic code
102

Research abstract

Project Summary Abstract The objective of this Phase I STTR project is to demonstrate feasibility of developing a selective affordable and pocket sized device to enable regular and quantitative monitoring of both Li and Na levels in the blood of patients with bipolar disorder BD which is one of the most common mental illnesses affecting over million Americans costing the healthcare system over $ billion dollars annually Even though lithium Li therapy is one of the most effective and affordable long term treatments for BD andlt of BD patients are prescribed with Li in large part because of its very narrow therapeutic window mM between ineffectiveness or very severe side effects Managing the inherent risk and maximizing the benefit of Li therapy requires convenient and regular monitoring of Li and Na whose level can fluctuate during Li therapy a technological niche that remains unfilled because of current POC devices are either too expensive bulky or vulnerable to interferences from other metal ions or species in blood To achieve the objective we will employ a combinatorial method called in vitro selection to obtain DNA molecules with enzymatic activity DNAzymes that are highly specific for either Li or Na from a large library of up to differences and will include negative selection to remove the populations that interact with known or anticipated interfering ions or species In addition we will repurpose the low cost and pocket sized blood glucose meter BGM into a more general meter for monitoring Li and Na levels The innovation lies in converting the selective Li or Na dependent cleavage by DNAzymes to effective release of an enzyme called invertase that can catalyze conversion of sucrose into glucose which can then be quantified using the BGM By combining DNAzymes with the BGM platform we can mitigate the risk associated with developing and manufacturing medical devices while ensuring the end product will be low cost convenient user friendly and amenable for scale up production Specifically we propose to employ in vitro selection to obtain and optimize Li or Na specific DNAzymes with high activity for cleavage We will develop solution assays for Li and Na relaying the selective recognition catalysis of DNAzymes to a BGM detectable glucose signal using invertase a protein that hydrolyses sucrose into glucose for both signal transduction and amplification The assay will be validated in clinical samples Finally we will develop disposable cartridges for BGM based POC monitoring of Li and Na The expected outcomes for this Phase I project are BGM based Li and Na assays with analytical performance validated in clinical samples and demonstrating the feasibility of performing the developed assays in a prototype cartridge system The product can be readily adapted to other biomarkers that will be relevant in assessing the states and needs of the patient Project narrative Although lithium therapy is one of the most effective and affordable long term treatments for bipolar disorder BD less than of BD patients are prescribed with lithium drug in large part because of its very narrow therapeutic window mM between ineffectiveness or very severe side effects By adapting widely available blood glucose meter and highly selective DNAzymes to detect lithium and sodium whose level is related to lithium level in the blood this STTR Phase I project will demonstrate feasibility of developing a novel affordable and pocket sized device to enable regular and quantitative monitoring of both Li and Na in the blood of BD patients Accomplishing the goal will improve effective and wider use of Li therapy in BD patients by enabling more precise control of Li dosing which will have a major impact in improving the lives of the patients with this common disorder and lowering their healthcare costs

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

11 SBIR/STTR records share this UEI (2012–2024). Reported award amounts total $4,066,166. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.